Neoplasia/BPH

	Positive predictive value of the prostate imaging reporting and data system combined with single related indicators in prostate cancer across different prostate zones. Front Oncol Shen X, Yang L, Wang S, Shen J. PMID: 41717420 [PubMed]
	Advancing CAR-T therapy in prostate cancer: overcoming the tumor microenvironment and enhancing efficacy. Front Oncol Zhou Z, Lao Y, Zhao K, Cheng L, Xiao X, Li W, Liu S, Kong X, Dong Z. PMID: 41717407 [PubMed]
	Tislelizumab Combined With Axitinib in Neoadjuvant Treatment of Locally Advanced Clear Cell Renal Cell Carcinoma: A Single-Center, Phase II Clinical Study. MedComm (2020) Yang W, Zhang S, Liu G, Li H, Wang X, Jiang B, Zhang G, Guo H, Ji C. PMID: 41716961 [PubMed]
	Blood inflammatory markers combined with tumor markers for differentiating benign prostatic hyperplasia from prostate cancer. Front Med (Lausanne) Liu Z, Yang X, Hou X, Du P, Jia K. PMID: 41716796 [PubMed]
	Re: Rui M. Bernardino, Leyi B. Yin, Katherine Lajkosz, et al. Intraductal Carcinoma Predicts Poor Response to Neoadjuvant Therapy in High-risk Prostate Cancer: A Retrospective Analysis of a Prospective Trial. Eur Urol Open Sci 2025;82:52-8. Eur Urol Open Sci Wu W, Li N, Zhang H. PMID: 41716568 [PubMed]
	A high-grade undifferentiated prostate malignancy in a young male suggestive of male adnexal tumour of Wolffian origin - A rare case and diagnostic challenge. Urol Case Rep Klein Nulend R, Lockhart K, Tree K, Tran LN, Matti B, Foon Y, Moghimi A, Wong D, Butler J, Kim LH, Wang A, Patel MI. PMID: 41716524 [PubMed]
	Evidence for the Additional Health Benefits Associated with Phosphodiesterase 5 Inhibitors when Used for Treating Erectile Dysfunction, with a Focus on Prostate Cancer Patients and Other Associated Conditions. World J Mens Health Naranjo A, Hackett GI, Smith S, Stephens H, Kinnaird W, Kirby M. PMID: 41714897 [PubMed - as supplied by publisher]
	Effects of Radiation Therapy on the Incidence of Bladder Cancer and Rectal Cancer in Patients with Prostate Cancer: A Nationwide Nested Case-Control Study in Korean Population. World J Mens Health Kwon J, Jeon J, Lee HS, Jeon S, Bang S, Lee KS, Koo KC, Cho KS, Kim DK. PMID: 41714890 [PubMed - as supplied by publisher]
	The AI Act and the MDR post-market requirements for semiautonomous AI SaMD: a radiology case study in prostate cancer. Abdom Radiol (NY) Shojaei S, Yakar D, Vellinga N, Bozgo V, Kwee T, Huisman H, Mifsud Bonnici JP. PMID: 41714355 [PubMed - as supplied by publisher]
	Review of radiopharmaceutical therapy in prostate cancer. Urol Oncol Miller SR, Dewaraja Y, Rowe SP, Reichert ZR, Viglianti BL. PMID: 41714269 [PubMed - as supplied by publisher]
	Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Variants Detects Clinically Relevant Disease: 5-year Results from the IMPACT Study. Eur Urol Bancroft EK, Page EC, McHugh J, Thomas S, Taylor N, Pope J, Evans DG, Rothwell J, Grindedal EM, Maehle L, James P, McKinley J, Mascarenhas L, Side L, Thomas T, van Leerdam ME, van Asperen CJ, Kiemeney LALM, Ringelberg J, Vlaming M, Rønlund K, Osther PJS, Helfand BT, Hutten CG, Oldenburg RA, Cybulski C, Wokolorczyk D, Ong KR, Huber C, Salinas M, Feliubadaló L, Oosterwijk JC, van Zelst-Stams WAG, Cook J, Rosario DJ, Maxwell K, Powers J, Buys S, Lyman J, Ausems MGEM, Schmutzler RK, Rhiem K, Izatt L, Tripathi V, Teixeira MR, Cardoso M, Foulkes WD, Aprikian A, Davidson R, Longmuir M, Ruijs MWG, Blom EW, van Engelen K, Williams R, Andrews L, Murphy DG, Saya S, Halliday D, Walker L, Liljegren A, Carlsson S, Azzabi A, Jobson I, Snape K, Gowie M, Harris M, Tischkowitz M, Taylor A, Kirk J, Susman R, Chen-Shtoyerman R, Spigelman A, Pachter N, Ahmed M, Cajal TRY, Krajc M, Cleaver R, Cruellas M, Perez-Ballestero E, Brady AF, Gallagher D, Donaldson A, Barwell J, Nicolai N, Friedman E, Hall MJ, Greenhalgh L, Murthy V, Copakova L, McGrath JS, Cooke P, Arun B, Myhill K, Hogben M, Hussain S, Aaronson NK, Ardern-Jones A, Bangma CH, Castro E, Dearnaley D, Eccles DM, Tricker K, Falconer A, Gronberg H, Hamdy FC, Khoo V, Lilja H, Lindeman GJ, Lubinski J, Axcrona K, Mikropoulos C, Mitra A, Offman J, Rennert G, Suri M, Dudderidge T, IMPACT Study Collaborators, Brook MN, Kote-Jarai Z, Eeles RA. PMID: 41714267 [PubMed - as supplied by publisher]
	Neoadjuvant therapy in gall bladder cancer improves resectability and survival: a prospective study. HPB (Oxford) Lahiri A, Chowdhury S, Goel S, Assif Iqbal S, Aggarwal A, Garg P, Goel V, Talwar V, Sethi J, Singh S. PMID: 41714243 [PubMed - as supplied by publisher]
	Stratifying Risk and Treatment Benefit: A Model Predicting Overall Survival in Men with Metastatic De Novo Hormone-sensitive Prostate Cancer in Trials Investigating Docetaxel (the STOPCAP Collaboration). Eur Urol Focus Halabi S, Luo B, Yu C, Rydzewska LHM, Roy A, Kim H, Godolphin PJ, Murphy L, Carducci MA, Gravis G, Sfumato P, Boher JM, James ND, Tierney JF, Page D, Sweeney C, Guo S. PMID: 41714204 [PubMed - as supplied by publisher]
	Differential Response to (177)Lu-PSMA-617 in Patients with Tumor Suppressor Gene-Mutated Metastatic Castration-Resistant Prostate Cancer. J Nucl Med Pepin A, Doucette A, Narayan VK, Maxwell KN, Takvorian SU, O'Brien SR, Mankoff DA, Mulugeta PG, Taunk NK. PMID: 41714123 [PubMed - as supplied by publisher]
	Outcomes of a Phase II Interventional Clinical Trial of Prostate Bed Stereotactic Body Radiation Therapy for Prostate Cancer with High-Risk Features Following Radical Prostatectomy. Int J Radiat Oncol Biol Phys Vargas CE, Voss MM, Dodoo C, Wong W, Zhu A, Keole SR, Rwigema JC, Davis B, Stish BJ, Laughlin B, Daniels T. PMID: 41713512 [PubMed - as supplied by publisher]
	Efficacy and tolerability of hypofractionated and dose-boosted radiotherapy for localised prostate cancer: a systematic review and meta-analysis. Radiother Oncol Miszczyk M, Sohoni N, Smani S, Moll M, Alfarhan AR, Roessler N, Miyajima K, Inoue S, Marvaso G, Mastroleo F, Zamboglou C, Soeterik TF, Zilli T, Terlizzi M, Blanchard P, Rajwa P, Fazekas T, Ploussard G, An Y, Leapman MS, Blanck O, Jereczek-Fossa BA, Shariat SF. PMID: 41713502 [PubMed - as supplied by publisher]
	Nomogram-based risk classification for predicting response to metastasis-directed stereotactic body radiotherapy in PSMA PET-staged oligorecurrent prostate cancer (PORTAL): an international, retrospective cohort study. Lancet Oncol Soeterik TFW, Miszczyk M, Peters M, Bilski M, Francolini G, Garlatti P, Nicosia L, Alongi F, Mezeckis M, Kociolek J, Greco C, Techma, Huele EH, Teunissen FR, Westhoff PG, Vis W, Haverkort MAD, van der Voort van Zyp JRN, Intven MPW, van der Velden JM, Shariat SF, Eppinga WSC. PMID: 41713474 [PubMed - as supplied by publisher]
	[Multidisciplinary management of elderly patients with advanced prostate cancer]. Rev Esp Geriatr Gerontol Molina-Garrido MJ, Ramírez-Martín R, Sánchez Castellano C, Cruz Castellanos P, Sánchez García M, Ríos González E, de Cabo Ripoll M, Martín Ordóñez F, Acosta Rojas Á, Arribas L, Cassinello J. PMID: 41713351 [PubMed - as supplied by publisher]
	Microvessel density as a prognostic factor in renal cell carcinoma: A systematic review and meta-analysis with individual patient data reconstructed from previous Kaplanâ€’Meier curves. Cancer Treat Res Commun Sun S, Zhang H, Ma L. PMID: 41713310 [PubMed - as supplied by publisher]
	Survival Prediction in Patients With Bladder Cancer Undergoing Radical Cystectomy Using a Machine Learning Algorithm: Retrospective Single-Center Study. JMIR Perioper Med Causio FA, De Vita V, Nappi A, Sawaya M, Rocco B, Foschi N, Maioriello G, Russo P. PMID: 41712865 [PubMed - indexed for MEDLINE]

Articles 1 - 20 / 185647

Page 1 of 9283



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy